Dr. Charles A. Dinarello

Professor of Medicine in the Division of Infectious Diseases at the University of Colorado, Denver.  Dr. Dinarello is considered a founding father of cytokine biology and has received several awards from the medical community for his contributions.

Learn More

Treatment of Type 1 Diabetes

Omni Bio Pharmaceutical’s lead development program is evaluating an FDA approved, off-patent drug, Alpha-1 Antitrypsin ("AAT"), for the treatment of Type 1 diabetes.

Learn More

Alpha-1 Antitrypsin (AAT)

Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of bacterial and viral diseases, biohazards, diabetes and transplant rejection.

Learn More

Developing broad spectrum therapeutics using an existing FDA approved drug

Omni Bio Pharmaceutical, Inc. (OTC: OMBP) is an emerging biopharmaceutical company that has licensed therapies currently in development that have the potential to address unmet immunological diseases.  

Our core strategy is based on licensing issued and pending patents that cover new uses for an existing FDA-approved drug, Alpha-1 antitrypsin (AAT). We intend to leverage sponsored research, collaborations with existing AAT manufactures, and licensed patents for the development and commercialization of AAT in additional indications that exceed AAT’s current markets.

Learn more about alpha-1 antitrypsin (AAT)

Omni Bio Pharmaceutical, Inc.
Investor/Shareholder Call | April 17, 2012

Listen to conference call featuring Dr. James Crapo, CEO and Bob Ogden, CFO.
CLICK TO LISTEN

Omni Bio Pharmaceutical, Inc.
Corporate Presentation | March 2012

Download and view the latest in news and research from Omni Bio Pharmaceutical (OTC:OMBP).
DOWNLOAD

Omni Bio Pharmaceutical, Inc.
Shareholder Letter | April 2012

Download and view the latest shareholder letter from Omni Bio Pharmaceutical (OTC:OMBP).
DOWNLOAD

OmniBio Story

Watch this video to learn more about OmniBio's breakthrough research for Type 1 Diabetes.

Dr. Charles Dinarello discusses article he co-authored in Blood Magazine

From Our Blog

  1. OmniBio Chief Scientific Officer Co-Authors Paper on AAT Research Bob Ogden 17-Oct-2011

OmniBio proudly follows these fine groups and organizations

CU BDC
A1
CDF
JDRF
ADA